35 results about "Renal transplant" patented technology

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens.

The invention provides application of N6-(2-ethoxy)adenosine in preparation of preparations for treating renal failure. By virtue of the N6-(2-ethoxy) adenosine, levels of inosine and urea nitrogen in renal failure and renal ischemia reperfusion injury can be obviously reduced, and renal tubular epithelial cell apoptosis and kidney inflammations are inhibited. The N6-(2-ethoxy) adenosine can be applied to multiple treatment applications of renal failure, renal transplant, renal ischemia reperfusion injury, kidney stone lithotripsy inflammations and other nephritides.

A dietary supplement which is formulated for medical patients, particularly renal dialysis patients undergoing a peritoneal renal dialysis treatment regimen. The supplement includes a powdered mixture of calcium caseinate, whey protein, L-carnitine and arginine. The ingredients are typically formulated in a powdered form which can be easily added to and ingested with various foods. The supplement provides various nutritional benefits to renal dialysis patients, including the elevation of blood carnitine and albumin levels and the reduction of blood pressure in renal transplant patients.

The invention relates to a short peptide having a kidney protection function as well as a preparation method and application thereof. The short peptide having the kidney protection function is characterized in that the amino acid sequence of the short peptide is QEQLERALNSS. The preparation method is characterized by comprising the following steps: successively coupling Ser, Asn, Leu, Ala, Arg, Glu, Leu, Gln, Glu and Gln on serine which is based on resin as a vector; after cracking, and settling with ice ether so as to obtain coarse peptide; and purifying with a high performance liquid chromatography (HPLC) so as to obtain the product. The invention also discloses application of the short peptide having the kidney protection function in the aspects of preparing formulations for treating renal ischemia-reperfusion injury along with acute tubular necrosis, local renal tissue inflammation and renal tubular epithelium cell apoptosis which are caused by the renal ischemia-reperfusion injury. The invention provides a novel clinic medicament for preventing and treating the renal ischemia-reperfusion injury, thereby bringing good news for patients suffering renal transplant.

Provided herein are methods, compositions, and kits for diagnosing acute rejection of renal transplants using the gene expression profile of sets of classifier genes. Such methods and compositions are independent of external confounders such as recipient age, transplant center, RNA source, assay, cause of end-stage renal disease, co-morbidities, immunosuppression usage, and the like.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.

The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of T cell antigen receptor beta chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating T cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the T cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the T cell antigen receptor beta chains; carrying out high-throughput sequencing on the CDRs3 of the T cell antigen receptor beta chains, and carrying out DNA analysis on the T cell antigen receptor beta chains in the experimental group and the control group. The method for treating the CDRs3 of the T cell antigen receptor beta chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to increment of short-term and long-term survival rate of renal transplant recipients after transplantation.

The present invention belong to the field of Chinese medicine technology, and discloses a Chinese medicine extract and capsule preparation for curing chronic nephritis, renal failure and urinaemia, etc. and their preparation method. Said Chinese medicine extract is made up by using 13 Chinese medicinal materials of astragalus root, American ginseng, poria, ovate atractylodex root, rehmannia flower, cordyceps, eucommia bark, lyceum berry and others through a certain preparation method. Then the obtained extract is placed into the capsule so as to obtain the invented Chinese medicine extract capsule preparation.

The invention relates to the technical field of medical instruments, in particular to a continuous refrigeration system for kidney transplantation operation. The continuous refrigeration system comprises a kidney bag, a kidney bag opening, a kidney portal opening, an in-vitro ring, an in-vivo ring, a pull wire, an inner pull ring and an outer pull ring, the kidney bag opening is formed in the upper end of the kidney bag, a transplanted kidney and smoothie mixture enters the kidney bag through the kidney bag opening, the kidney portal opening is formed in the lower end of the kidney bag, the in-vitro ring is annularly arranged at the kidney bag opening and enables the kidney bag opening to be supported and expanded, the in-vivo ring is arranged on the kidney bag in an annular mode and arranged in the body of a patient of the transplanted kidney, the outer surface of the kidney bag is connected with the pull wire, the two ends of the pull wire protrude out of the kidney bag, the lower end of the pull wire is connected with the inner pull ring, and the upper end of the pull wire is connected with the outer pull ring. The kidney bag is pulled into the in-vivo kidney anastomosis position through the inner pull ring, the kidney bag is pulled out through the outer pull ring after an operation, and the problem that a kidney supply low-temperature protection bag is inconvenient to placein a human body and take out after the operation is solved.

The invention provides a rat CD4 antibody coated magnetic beads, a preparation method and an application therefor and a kit containing magnetic beads. The method for preparing the magnetic beads comprises the following steps of: washing the magnetic beads multiple times through different reagents, and removing the supernatant. The rat CD4 antibody coated magnetic beads can be prepared according tothe preparation method. The prepared rat CD4 antibody coated magnetic beads can be used in the kit, and used for detecting immunological rejection after rat kidney transplantation. Compared with theprior art, the invention has the advantages that the rat CD4 antibody coated magnetic beads prepared by the method for preparing the rat CD4 antibody coated magnetic beads is combined with an immune cell function measurement kit ImmuKnow TW-Cylex , and can be used for detecting the immunological rejection after the rat kidney transplantation.

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of B cell antigen receptor H chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating B cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the B cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the B cell antigen receptor H chains; carrying out high-throughput sequencing on the CDRs3 of the B cell antigen receptor H chains, and carrying out DNA analysis on the B cell antigen receptor H chains in the experimental group and the control group. The method for treating the CDRs3 of the B cell antigen receptor H chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to improvement of the treatment of patients with end-stage renal disease.

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammations, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia.

The invention belongs to the technical field of medical instruments, and discloses a blood vessel anastomat for a kidney transplantation operation. An inner tube main body comprises a left inner tube; fixed teeth fixedly connected with the left inner tube are arranged on the left inner tube; a middle tube fixedly connected with the left inner tube is arranged on the left inner tube; a right inner tube fixedly connected with the middle tube is arranged on the middle tube; fixing teeth fixedly connected with the right inner tube are arranged on the right inner tube; and hollow grids are arranged on the left inner tube, the middle tube and the right inner tube. According to the blood vessel anastomat, through the inner tube main body made of a shape memory material, the left inner tube and the right inner tube are expanded at phase-change temperature, and the middle tube is shrunk at the phase-change temperature, to make blood vessels on the two sides attached.

The invention discloses a kidney transplantation specimen storage device, and relates to the field of medical instruments. The kidney transplantation specimen storage device comprises an upper box body and a lower box body which are fixedly connected, wherein the upper end of the upper box body is provided with a movable box door, a specimen containing mechanism is arranged in the upper box body,a driving mechanism is arranged in the lower box body, and the driving mechanism can drive the specimen containing mechanism to ascend or descend; and the kidney transplantation specimen storage device further comprises a cold air system, a temperature sensor and a main controller, the temperature sensor and the main controller are arranged on the upper box body, and the cold air system, the driving mechanism and the temperature sensor are electrically connected with the main controller. Through the design, the kidney transplantation specimen storage device is convenient to use and safe in storage.

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose.

The invention relates to a kidney transplantation calculus urination observation device which comprises a cylinder, the cylinder is connected with a clamping mechanism, the top of a connecting pipe communicates with a sleeve, the top of the sleeve communicates with an air bag, the top of the air bag communicates with an exhaust pipe, first sliding grooves are formed in the inner walls of the two sides of the exhaust pipe correspondingly, and first sliding blocks are slidably connected into the first sliding grooves; an exhaust column is fixed between the two first sliding blocks, exhaust holes are formed in the bottom and one side of the exhaust column, second sliding grooves are formed in the inner walls of the two sides of the sleeve, second sliding blocks are slidably connected into the second sliding grooves, an air inlet disc is fixed between the two second sliding blocks, an air inlet hole is formed in the top of the air inlet disc in a penetrating mode, and a fixing rod is fixed into the sleeve; the top of the barrel is in threaded connection with a barrel cover, and the top of the barrel cover communicates with a liquid inlet pipe; according to the drainage assisting device, air in the cylinder body is pumped out through the air bag, so that negative pressure can be formed in the cylinder body, urine gathered in a urinary catheter and a bladder is sucked out through the negative pressure, and therefore the drainage assisting function is achieved.

Disclosed are novel methods of assessing transplant rejection status in a transplant recipient, such as a kidney transplant recipient. The diagnostic method identifies stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes using measurement of TCR subunit repertoire diversity. The proportion of unique TCR alpha and beta subunit sequences to total unique TCR subunit sequences (total sequences for alpha, beta, delta, and gamma subunits) provides a diagnostic measure that can identify stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes. Methods of treatment include administration of a suitable treatment if antibody mediated rejection or cell mediated rejection is detected.

The invention discloses an early diagnosis and detection system used for a BKV (BK polyomavirus), and application of the early diagnosis and detection system, and particularly provides a primer probesystem used for the early diagnosis and detection of the BKV, a kit including the above primer probe, and the purposes of the primer probe system and the kit. The primer probe system disclosed by theinvention has a wider coverage degree, high specificity, higher sensitivity and a larger clinic application potential, and is favorable for effectively preventing BKV related diseases, and the qualityof life of renal transplant recipients can be improved.

The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.

The invention relates to the technical field of medical instruments, in particular to a continuous refrigeration system for kidney transplantation operation, which is used for refrigerating kidney from the beginning of kidney transplantation operation to the opening of artery and vein of the kidney and comprises a kidney bag, an in-vitro ring and an in-vivo ring, a bag opening is formed in one end of the kidney bag, the kidney and crushed ice enter the kidney bag through the bag opening, the in-vitro ring and the in-vivo ring are arranged on the kidney bag at intervals, and leading-out ends are arranged on the outer side and the inner side of the bottom of the kidney bag. The local length of the kidney bag is supported to form the through circulation channel, the kidney enters the kidney bag through the circulation channel so as to obtain a carrier entering a human body, operation is easy, convenient and rapid, the kidney bag can adapt to laparoscopic surgery due to the arrangement of the leading-out end, and by pulling the leading-out end on the outer side of the bottom of the kidney bag, the kidney can be conveniently pulled to the kidney anastomosis position, the kidney bag can be pulled out of the body by pulling the leading-out end on the inner side of the bottom of the kidney bag after operation, and it is guaranteed that the kidney is in a continuous low-temperature environment by adding crushed ice to the bag opening for multiple times.